MAURI MARIO
- U08, Piano: 4, Stanza: 4039
Pubblicazioni
Elli, E., Mauri, M., D’Aliberti, D., Crespiatico, I., Fontana, D., Redaelli, S., et al. (2024). Idiopathic erythrocytosis: a germline disease?. CLINICAL AND EXPERIMENTAL MEDICINE, 24(1) [10.1007/s10238-023-01283-y]. Dettaglio
Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD [10.1182/blood.2023021349]. Dettaglio
Aroldi, A., Mauri, M., Ramazzotti, D., Villa, M., Malighetti, F., Crippa, V., et al. (2023). Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 27(20 (October 2023)), 3053-3064 [10.1111/jcmm.17868]. Dettaglio
Difrancesco, J., Ragona, F., Murano, C., Frosio, A., Melgari, D., Binda, A., et al. (2023). A novel de novo HCN2 loss-of-function variant causing developmental and epileptic encephalopathy treated with a ketogenic diet. EPILEPSIA, 34(12 (December 2023)), 222-228 [10.1111/epi.17777]. Dettaglio
Malighetti, F., Arosio, G., Manfroni, C., Mauri, M., Villa, M., Manghisi, B., et al. (2023). DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients. HEMASPHERE, 7(3) [10.1097/HS9.0000000000000852]. Dettaglio